Please use this identifier to cite or link to this item:
|Title:||Drug, delivery and devices for diabetic retinopathy (3Ds in DR)||Authors:||Natarajan, Jayaganesh V.
Lim, Tock Han
Venkatraman, Subbu S.
|Issue Date:||2016||Source:||Nirmal, J., Radhakrishnan, K., Moreno, M., Natarajan, J. V., Laude, A., Lim, T. H., et al. (2016). Drug, delivery and devices for diabetic retinopathy (3Ds in DR). Expert Opinion on Drug Delivery, 13(11), 1625-1637.||Series/Report no.:||Expert Opinion on Drug Delivery||Abstract:||Introduction: Diabetic Retinopathy (DR) is one of the most common causes of blindness among the working population worldwide. Clearly, there is an unmet clinical need to find better treatment options for DR. Areas covered: The literature search was conducted on PubMed with no limitation on language or year of publication. The review focuses on the clinically used drugs/proteins along with a brief background on the pathophysiology of DR. The major focus of this review revolves around three treatment approaches involving drugs/proteins, drug delivery formulations and drug delivery devices. In each category, major advances are discussed along with the possible solutions. We have also discussed the various modes of administration that are currently being evaluated in the clinic. An attempt has been made to address the potential targeted site of action for DR drug delivery, and also to understand the role of Blood Retinal Barrier (BRB). Expert Opinion: In the current scenario, although there have been some advances in the drug delivery devices for delivering drugs/proteins, there are still challenges to be overcome with regard to the particulate systems. For long-term success of DR therapeutics, research options should consider taking into account the 3Ds (drug, delivery and devices).||URI:||https://hdl.handle.net/10356/84621
|ISSN:||1742-5247||DOI:||10.1080/17425247.2016.1188800||Rights:||© 2016 Informa UK Limited. This is the author created version of a work that has been peer reviewed and accepted for publication in Expert Opinion on Drug Delivery, published by Taylor & Francis on behalf of Informa UK Limited. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1080/17425247.2016.1188800].||Fulltext Permission:||open||Fulltext Availability:||With Fulltext|
|Appears in Collections:||MSE Journal Articles|
Files in This Item:
|Drug delivery and devices for diabetic retinopathy 3Ds in DR.pdf||960.26 kB||Adobe PDF|
Updated on Mar 10, 2021
Updated on Mar 3, 2021
Page view(s) 50318
Updated on Apr 18, 2021
Updated on Apr 18, 2021
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.